Study #2023-0754
A phase III, randomized, controlled, global multicenter study to evaluate the efficacy and safety of oral Tinengotinib versus physician's choice in subjects with fibroblast growth factor receptor (FGFR)-altered, chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308).
MD Anderson Study Status
Enrolling
Treatment Agent
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
Description
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cholangiocarcinoma
Study phase:
Phase III
Physician name:
Milind Javle
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.